Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio for Now

XRAY's digital dentistry, R&D and restructuring support growth, but CAD/CAM, implants, SureSmile and tariff pressures pose near-term risks.

Zacks Investment Research • Sep 17, 2026

XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure

XRAY beat Q2 earnings and revenue estimates, held 2026 guidance and improved cash flow, but falling sales and margin pressure cloud the recovery.

Zacks Investment Research • Sep 8, 2026

Did Dentsply Sirona Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

PRNewsWire • Sep 7, 2026

Dentsply Sirona to Participate in the Baird 2026 Global Healthcare Conference

CHARLOTTE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Baird 2026 Global Healthcare Conference. Management is scheduled to present on Tuesday, September 15, 2026, at 11:25 a.m. ET.

GlobeNewsWire • Sep 3, 2026

Hayes: "950 Billion Reasons" to Buy Bonds, PFE & XRAY Buy Opportunities

"I'll give you 950 billion reasons to buy bonds right now," says Thomas Hayes, who gives a contrarian take on why investors should bolster their portfolios in fixed income. He discusses the "seasonality effect," a crowded AI trade, a complicated geopolitical picture, and a steady rise in crude oil as components he sees leading a lasting bond rally.

New At-Home Surity™ Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinence

New system completes the Surity™  portfolio of external catheters for both men and women Integrates into daily routines to help support management of urinary incontinence at home Designed to operate quietly overnight, new Surity™ System helps minimize nighttime interruptions to support comfort and rest MÖLNDAL, Sweden, Aug. 19, 2026 /PRNewswire/ -- Wellspect HealthCare today announced the U.S. launch of the Surity™ Urinary Management System, a discreet at-home urine collection device designed to support people living with urinary incontinence and those who help care for them. This completes the full Surity™ portfolio in the U.S., following the introduction of the Surity™ Female and Male External Catheters earlier this year.

PRNewsWire • Aug 19, 2026

DENTSPLY SIRONA Q2 Earnings Call Highlights

DENTSPLY SIRONA NASDAQ: XRAY reported second-quarter 2026 revenue of $898 million, down 4.1% on a reported basis and 6.3% on a constant-currency basis, as the dental products company continued its turnaround plan amid lower volumes in several businesses and distributor inventory reductions in Europe.

MarketBeat • Aug 7, 2026

XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales

DENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.

Zacks Investment Research • Aug 7, 2026

Here's What Key Metrics Tell Us About Dentsply (XRAY) Q2 Earnings

The headline numbers for Dentsply (XRAY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Aug 7, 2026

DENTSPLY SIRONA Inc. (XRAY) Q2 2026 Earnings Call Transcript

DENTSPLY SIRONA Inc. (XRAY) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 7, 2026